Feed KYMR
KY

Kymera Therapeutics

KYMR · NASDAQ

$117.67 -1.24% (-$1.47)
1M -2.79%
Market Cap $9.68B
P/E Ratio -
Div. Yield -
ROE 21.50%
Piotroski F-Score Moderate
4/9
Valuation
10 /100
Expensive
P/S 92.19x
P/B 6.41x
P/E N/A
Growth
22 /100
Declining
Rev. growth 5.75%
Book val. growth 47.71%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 101.99%
Net margin 285.41%
Op. margin 333.54%
Quality
1 /100
Poor
ROIC 22.00%
ROE 21.50%
ROA 18.21%
Debt
69 /100
Low
Debt/Equity 0.05x
Current ratio 9.83x
Int. coverage -1,420.20x
Stability
27 /100
Unstable
Beta 1.97x
Rev. volatility 56.79%
EPS volatility 19.39%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o KYMR
Online

O podjetju

Kymera Therapeutics is a U.S.-based biotechnology company that specializes in the development of therapeutics aimed at protein modulation using advanced protein degradation technologies. The company uses an innovative approach to treating diseases by focusing on selectively degrading faulty proteins in the body rather than blocking them. Kymera Therapeutics focuses on developing drugs for the treatment of oncology, immunology, and rare diseases, with its technology holding the potential to significantly change the way many serious health issues are treated.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Nello Mainolfi

Employees

273

Headquarters

Watertown

Prihajajoči dogodki

03 NOV.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.